Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Adjuvant tislelizumab with or without platinum doublet chemotherapy after resection for high-risk esophageal squamous cell carcinoma
ChiCTR2100045651Phase 3Recruiting
- Sponsor
- Cancer Hospital, Chinese Academy of Medical Sciences
- Start
- May 2021
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of tislelizumab in Esophageal Squamous Cell Carcinoma (ESCC) (2 arms), sponsored by Cancer Hospital, Chinese Academy of Medical Sciences. Primary endpoint: Disease-free survival. Started May 2021; status: recruiting.
02
Drugs
tislelizumab
03
Conditions
Esophageal Squamous Cell Carcinoma (ESCC)
Beyond the preview
Go deeper on ChiCTR2100045651.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2100045651.